ArticleCureus2025
Prostate-Specific Membrane Antigen Positron Emission Tomography-Detected Intrahepatic Cholangiocarcinoma in a Patient With Metastatic Castration-Resistant Prostate Cancer: Dual Cancer Management With Pluvicto and Intensity-Modulated Radiation Therapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prospective head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intrahepatic cholangiocarcinoma (ICC) is a rare hepatobiliary malignancy often diagnosed at advanced stages due to its silent progression. Prostate-specific membrane antigen (PSMA) PET/CT, primarily used in prostate cancer, can incidentally detect unrelated malignancies. In a patient with metastatic castration-resistant prostate cancer (mCRPC), PSMA PET/CT revealed a liver lesion initially presumed metastatic. However, lack of uptake on post-therapy single-photon emission computed tomography/CT (SPECT/CT) prompted further evaluation, and MRI with biopsy confirmed ICC. The patient received intensity-modulated radiation therapy (IMRT) for ICC, stereotactic body radiation therapy (SBRT) for prostate metastases, and continued Lu-177 PSMA-617 therapy. This case highlights the incidental diagnostic value of PSMA PET and the importance of post-therapy imaging and multidisciplinary care in managing complex cancer presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.